Key takeaways
- • Frequency: Common — 10-15% in trials.
- • Trial reference: SURMOUNT-1 (tirzepatide) (10-21%).
- • Management: typically resolves within 4-8 weeks as the body adapts.
- • When to call doctor: see red-flag list below.
Why this happens
GLP-1-induced changes in gut motility can alter intestinal transit time. The effect typically diminishes as the gut adapts to the medication.
How to manage it
- Stay hydrated with electrolyte drinks (Pedialyte, Liquid IV) — water alone may not be enough
- BRAT diet during acute episodes (bananas, rice, applesauce, toast)
- Avoid: caffeine, alcohol, dairy, very spicy foods, artificial sweeteners
- OTC anti-diarrheal (loperamide/Imodium) is generally safe for occasional use — confirm with prescriber
GLP1Zoom doesn't prescribe — these are general management guidance from FDA labels and clinical trial reports. Personalized recommendations require your prescribing clinician.
When to call your doctor
Red flags — seek medical attention
- • Diarrhea >3 days with no improvement
- • Blood in stool
- • Severe abdominal pain or cramping
- • Signs of dehydration: dark urine, dizziness, dry mouth
- • Fever >101°F
Drug-specific notes
- Wegovy: Diarrhea ~30% peak, ~6% by week 68
- Zepbound: Diarrhea ~21% at maximum doses
Other GLP-1 symptoms
Gastrointestinal
Nausea on GLP-1 medications
Gastrointestinal
Constipation on GLP-1 medications
Systemic
Fatigue on GLP-1 medications
Neurological
Headache on GLP-1 medications
Skin / Hair
Hair loss on GLP-1 medications
Gastrointestinal
Gallbladder issues on GLP-1 medications
Symptom management is general guidance based on FDA-approved prescribing information. Always discuss specifics with your prescribing clinician. In medical emergencies, call 911 or go to the nearest emergency department. Full disclaimer.
References
Endocrine Society Clinical Practice Guideline: Pharmacological Management of Obesity(2015)
STEP-1 trial: Once-Weekly Semaglutide in Adults with Overweight or Obesity (Wilding et al., NEJM)(2021)
SURMOUNT-1 trial: Tirzepatide Once Weekly для Treatment of Obesity (Jastreboff et al., NEJM)(2022)
Glucagon-Like Peptide-1 Receptor Agonists: Mechanisms и Clinical Use (Drucker, Cell Metabolism)(2018)
Tirzepatide GIP/GLP-1 Dual Agonism: Mechanism Review (Lancet Diabetes & Endocrinology)(2021)
GLP-1 Effects on Gastric Emptying: Pharmacology Review (American J Physiology)(2020)
SUSTAIN-6 trial: Semaglutide and Cardiovascular Outcomes (Marso et al., NEJM)(2016)
SURPASS-2 trial: Tirzepatide vs Semaglutide в Type 2 Diabetes (Frias et al., NEJM)(2021)
LEADER trial: Liraglutide and Cardiovascular Outcomes в T2D (Marso et al., NEJM)(2016)